Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 1
1996 2
1997 2
1999 1
2000 1
2001 1
2002 2
2003 5
2004 1
2005 1
2006 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenström's macroglobulinemia.
Vela-Ojeda J, García-Ruiz Esparza MA, Padilla-González Y, Rosas-Cabral A, García-Chávez J, Xolotl-Castillo M, Salazar-Exaire D, Arenas-Osuna J, Aviña-Zubieta JA, Vadillo-Buenfil M, Abraham-Majluf S. Vela-Ojeda J, et al. Among authors: vadillo buenfil m. J Interferon Cytokine Res. 2002 Oct;22(10):1013-6. doi: 10.1089/107999002760624233. J Interferon Cytokine Res. 2002. PMID: 12433280 Clinical Trial.
Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.
Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar SS, Schally AV. Pinski J, et al. Among authors: vadillo buenfil m. Endocrinology. 1996 Aug;137(8):3430-6. doi: 10.1210/endo.137.8.8754771. Endocrinology. 1996. PMID: 8754771
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
Vela-Ojeda J, García-Ruiz Esparza MA, Reyes-Maldonado E, Jiménez-Zamudio L, Moreno-Lafont M, García-Latorre E, Ramírez-Sanjuan E, Montiel-Cervantes L, Tripp-Villanueva F, García-León LD, Ayala-Sánchez M, Rosas-Cabral A, Aviña-Zubieta JA, Galindo-Rodríguez G, Vadillo-Buenfil M, Salazar-Exaire D. Vela-Ojeda J, et al. Among authors: vadillo buenfil m. Ann Hematol. 2004 May;83(5):295-301. doi: 10.1007/s00277-003-0822-y. Epub 2003 Dec 5. Ann Hematol. 2004. PMID: 15060749
Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord.
Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, Fuentes-Garcia M, Cardenas-Cornejo I, Comaru-Schally AM, Schally AV. Gonzalez-Barcena D, et al. Among authors: vadillo buenfil m. Urology. 1995 Feb;45(2):275-81. doi: 10.1016/0090-4295(95)80018-2. Urology. 1995. PMID: 7531902 Clinical Trial.
19 results